Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3da168962c8dbb03e022f08e6ec72ac7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9da38f0a8e4fb6e9b77e8384886d1ae9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3b7edd3693b55c0fd41df267c299f173 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-111 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-117 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C40B30-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-117 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
filingDate |
2006-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f423053d8ac6928e17c24f05ad42692 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a459ac5660b8decd7f4b546d7bd13f54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e89e9d0266977ed7892410b766fcf13 |
publicationDate |
2009-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2009209620-A1 |
titleOfInvention |
Direct Reversal Of The Suppressive Function Of CD4+Regulatory T Cells Via Toll-Like Receptor 8 Signaling |
abstract |
CD4 + regulatory T (Treg) cells profoundly suppress host immune responses and thus protect against autoimmune disease while restricting desired immune responses such as antitumor immunity. Synthetic phosphorothioate-protected, guanosine-containing oligonucleotides can directly reverse the suppressive activity of Treg cells without involving dendritic cells. This effect appears to be transduced by signaling through Toll-like receptor (TLR) 8 and engagement of the MyD88 and IRAK4 molecules in Treg cells. Stimulation of Treg cells with natural ligands for human TLR8 recapitulated the effect of the synthetic guanosine-containing oligonucleotides . |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8962652-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9161934-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2968501-A4 |
priorityDate |
2005-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |